Shopping Cart 0
Cart Subtotal
USD 0

Generics North America (NAFTA) Industry Guide 2013-2022

Restricted to one authorized user; Open on 1 PC/ mobile / Tablet only.
Print Option: Yes
Copy Option: No
Deliverable Format : PDF Via Email

Single User License
USD 795

Restricted to one authorized user; Open on 1 PC/ mobile / Tablet only.
Print Option: Yes
Copy Option: No
Deliverable Format : PDF Via Email

Site License
USD 1590

Multiple Users within the Company/ Enterprise
Print Option: Yes
Copy Option: Yes
Deliverable Format : Excel, PDF Via Email

Corporate User License
USD 2385
  • Details
  • Table Of Content
  • Licence Rights
  • Section Purchase
  • Products and Companies

Details

Generics North America (NAFTA) Industry Guide 2013-2022

Summary

The NAFTA Generics industry profile provides top-line qualitative and quantitative summary information including: market size (value and volume 2013-17, and forecast to 2022). The profile also contains descriptions of the leading players including key financial metrics and analysis of competitive pressures within the market.

Key Questions Answered:

- What was the size of the NAFTA generics market by value in 2017?

- What will be the size of the NAFTA generics market in 2022?

- What factors are affecting the strength of competition in the NAFTA generics market?

- How has the market performed over the last five years?

- How large is the NAFTA generics market in relation to its regional counterparts?

Scope

Essential resource for top-line data and analysis covering the NAFTA generics market. Includes market size data, textual and graphical analysis of market growth trends and leading companies.

- The North American Free Trade Agreement (NAFTA) is a trade agreement between the countries in North America: the US, Canada and Mexico. The generics industry within the NAFTA countries had a total market value of USD 1,13,947.8 million in 2017.The Mexico was the fastest growing country, with a CAGR of 14.7% over the 2013-17 period.

- Within the generics industry, the US is the leading country among the NAFTA bloc, with market revenues of USD 1,02,919.9 million in 2017. This was followed by Mexico and Canada, with a value of USD 6,014.0 and USD 5,014.0 million, respectively.

- The US is expected to lead the generics industry in the NAFTA bloc, with a value of USD 1,30,127.0 million in 2022, followed by Mexico and Canada with expected values of USD 9,175.2 and USD 5,616.0 million, respectively.

Reasons to buy

- Save time carrying out entry-level research by identifying the size, growth, and leading players in the NAFTA generics market

- Use the Five Forces analysis to determine the competitive intensity and therefore attractiveness of the NAFTA generics market

- Leading company profiles reveal details of key generics market players' NAFTA operations and financial performance

- Add weight to presentations and pitches by understanding the future growth prospects of the NAFTA generics market with five year forecasts by both value and volume

- Compares data from the US, Canada and Mexico, alongside individual chapters on each country

READ MORE

Table Of Content

Scope

Table of Contents

Introduction 8

What is this report about? 8

Who is the target reader? 8

How to use this report 8

Definitions 8

NAFTA Generics 9

Industry Outlook 9

Generics in Canada 12

Market Overview 12

Market Data 13

Market Segmentation 15

Market outlook 16

Five forces analysis 18

Macroeconomic indicators 25

Generics in Mexico 27

Market Overview 27

Market Data 28

Market Segmentation 30

Market outlook 31

Five forces analysis 33

Macroeconomic indicators 39

Generics in The United States 41

Market Overview 41

Market Data 42

Market Segmentation 44

Market outlook 45

Five forces analysis 47

Macroeconomic indicators 53

Company Profiles 55

Leading Companies 55

Appendix 72

Methodology 72

About MarketLine 73


List Of Figure

List of Figures

Figure 1: NAFTA countries generics industry, revenue (USD m), 2013-22

Figure 2: NAFTA countries generics industry, revenue (USD m), 2013-17

Figure 3: NAFTA countries generics industry forecast, revenue (USD m), 2017-22

Figure 4: Canada generics market value: USD million, 2013-17

Figure 5: Canada generics market volume: % of total pharma, 2013-17

Figure 6: Canada generics market geography segmentation: % share, by value, 2017

Figure 7: Canada generics market value forecast: USD million, 2017-22

Figure 8: Canada generics market volume forecast: % of total pharma, 2017-22

Figure 9: Forces driving competition in the generics market in Canada, 2017

Figure 10: Drivers of buyer power in the generics market in Canada, 2017

Figure 11: Drivers of supplier power in the generics market in Canada, 2017

Figure 12: Factors influencing the likelihood of new entrants in the generics market in Canada, 2017

Figure 13: Factors influencing the threat of substitutes in the generics market in Canada, 2017

Figure 14: Drivers of degree of rivalry in the generics market in Canada, 2017

Figure 15: Mexico generics market value: USD million, 2013-17

Figure 16: Mexico generics market volume: % of total pharma, 2013-17

Figure 17: Mexico generics market geography segmentation: % share, by value, 2017

Figure 18: Mexico generics market value forecast: USD million, 2017-22

Figure 19: Mexico generics market volume forecast: % of total pharma, 2017-22

Figure 20: Forces driving competition in the generics market in Mexico, 2017

Figure 21: Drivers of buyer power in the generics market in Mexico, 2017

Figure 22: Drivers of supplier power in the generics market in Mexico, 2017

Figure 23: Factors influencing the likelihood of new entrants in the generics market in Mexico, 2017

Figure 24: Factors influencing the threat of substitutes in the generics market in Mexico, 2017

Figure 25: Drivers of degree of rivalry in the generics market in Mexico, 2017

Figure 26: United States generics market value: USD billion, 2013-17

Figure 27: United States generics market volume: % of total pharma, 2013-17

Figure 28: United States generics market geography segmentation: % share, by value, 2017

Figure 29: United States generics market value forecast: USD billion, 2017-22

Figure 30: United States generics market volume forecast: % of total pharma, 2017-22

Figure 31: Forces driving competition in the generics market in the United States, 2017

Figure 32: Drivers of buyer power in the generics market in the United States, 2017

Figure 33: Drivers of supplier power in the generics market in the United States, 2017

Figure 34: Factors influencing the likelihood of new entrants in the generics market in the United States, 2017

Figure 35: Factors influencing the threat of substitutes in the generics market in the United States, 2017

Figure 36: Drivers of degree of rivalry in the generics market in the United States, 2017

Figure 37: Mylan N.V.: revenues & profitability

Figure 38: Mylan N.V.: assets & liabilities

Figure 39: Novartis AG: revenues & profitability

Figure 40: Novartis AG: assets & liabilities

Figure 41: Pfizer Inc.: revenues & profitability

Figure 42: Pfizer Inc.: assets & liabilities

Figure 43: Teva Pharmaceutical Industries Limited: revenues & profitability

Figure 44: Teva Pharmaceutical Industries Limited: assets & liabilities


List Of Table

List of Tables

Table 1: NAFTA countries generics industry, revenue (USD m), 2013-22

Table 2: NAFTA countries generics industry, revenue (USD m), 2013-17

Table 3: NAFTA countries generics industry forecast, revenue (USD m), 2017-22

Table 4: Canada generics market value: USD million, 2013-17

Table 5: Canada generics market volume: % of total pharma, 2013-17

Table 6: Canada generics market geography segmentation: USD million, 2017

Table 7: Canada generics market value forecast: USD million, 2017-22

Table 8: Canada generics market volume forecast: % of total pharma, 2017-22

Table 9: Canada size of population (million), 2013-17

Table 10: Canada gdp (constant 2005 prices, USD billion), 2013-17

Table 11: Canada gdp (current prices, USD billion), 2013-17

Table 12: Canada inflation, 2013-17

Table 13: Canada consumer price index (absolute), 2013-17

Table 14: Canada exchange rate, 2013-17

Table 15: Mexico generics market value: USD million, 2013-17

Table 16: Mexico generics market volume: % of total pharma, 2013-17

Table 17: Mexico generics market geography segmentation: USD million, 2017

Table 18: Mexico generics market value forecast: USD million, 2017-22

Table 19: Mexico generics market volume forecast: % of total pharma, 2017-22

Table 20: Mexico size of population (million), 2013-17

Table 21: Mexico gdp (constant 2005 prices, USD billion), 2013-17

Table 22: Mexico gdp (current prices, USD billion), 2013-17

Table 23: Mexico inflation, 2013-17

Table 24: Mexico consumer price index (absolute), 2013-17

Table 25: Mexico exchange rate, 2013-17

Table 26: United States generics market value: USD billion, 2013-17

Table 27: United States generics market volume: % of total pharma, 2013-17

Table 28: United States generics market geography segmentation: USD billion, 2017

Table 29: United States generics market value forecast: USD billion, 2017-22

Table 30: United States generics market volume forecast: % of total pharma, 2017-22

Table 31: United States size of population (million), 2013-17

Table 32: United States gdp (constant 2005 prices, USD billion), 2013-17

Table 33: United States gdp (current prices, USD billion), 2013-17

Table 34: United States inflation, 2013-17

Table 35: United States consumer price index (absolute), 2013-17

Table 36: United States exchange rate, 2013-17

Table 37: Apotex, Inc.: key facts

Table 38: Mylan N.V.: key facts

Table 39: Mylan N.V.: key financials (USD )

Table 40: Mylan N.V.: key financial ratios

Table 41: Novartis AG: key facts

Table 42: Novartis AG: key financials (USD )

Table 43: Novartis AG: key financial ratios

Table 44: Pfizer Inc.: key facts

Table 45: Pfizer Inc.: key financials (USD )

Table 46: Pfizer Inc.: key financial ratios

Table 47: Teva Pharmaceutical Industries Limited: key facts

Table 48: Teva Pharmaceutical Industries Limited: key financials (USD )

Table 49: Teva Pharmaceutical Industries Limited: key financial ratios

Licence Rights

Single User License:
Report can be used by individual purchaser only

Site License: 
Report can be shared by unlimited users within one corporate location, e.g. a regional office

Corporate User License:  
Report can be shared globally by unlimited users within the purchasing corporation e.g. all employees of a single company

Section Purchase

To know more information on Purchase by Section, please send a mail to support@kenresearch.com

Products and Companies

Products

MarketLine, Pharmaceuticals and Healthcare, Generics , NAFTA

Generics North America (NAFTA) Industry Guide 2013-2022

Summary

The NAFTA Generics industry profile provides top-line qualitative and quantitative summary information including: market size (value and volume 2013-17, and forecast to 2022). The profile also contains descriptions of the leading players including key financial metrics and analysis of competitive pressures within the market.

Key Questions Answered:

- What was the size of the NAFTA generics market by value in 2017?

- What will be the size of the NAFTA generics market in 2022?

- What factors are affecting the strength of competition in the NAFTA generics market?

- How has the market performed over the last five years?

- How large is the NAFTA generics market in relation to its regional counterparts?

Scope

Essential resource for top-line data and analysis covering the NAFTA generics market. Includes market size data, textual and graphical analysis of market growth trends and leading companies.

- The North American Free Trade Agreement (NAFTA) is a trade agreement between the countries in North America: the US, Canada and Mexico. The generics industry within the NAFTA countries had a total market value of USD 1,13,947.8 million in 2017.The Mexico was the fastest growing country, with a CAGR of 14.7% over the 2013-17 period.

- Within the generics industry, the US is the leading country among the NAFTA bloc, with market revenues of USD 1,02,919.9 million in 2017. This was followed by Mexico and Canada, with a value of USD 6,014.0 and USD 5,014.0 million, respectively.

- The US is expected to lead the generics industry in the NAFTA bloc, with a value of USD 1,30,127.0 million in 2022, followed by Mexico and Canada with expected values of USD 9,175.2 and USD 5,616.0 million, respectively.

Reasons to buy

- Save time carrying out entry-level research by identifying the size, growth, and leading players in the NAFTA generics market

- Use the Five Forces analysis to determine the competitive intensity and therefore attractiveness of the NAFTA generics market

- Leading company profiles reveal details of key generics market players' NAFTA operations and financial performance

- Add weight to presentations and pitches by understanding the future growth prospects of the NAFTA generics market with five year forecasts by both value and volume

- Compares data from the US, Canada and Mexico, alongside individual chapters on each country

READ MORE

Scope

Table of Contents

Introduction 8

What is this report about? 8

Who is the target reader? 8

How to use this report 8

Definitions 8

NAFTA Generics 9

Industry Outlook 9

Generics in Canada 12

Market Overview 12

Market Data 13

Market Segmentation 15

Market outlook 16

Five forces analysis 18

Macroeconomic indicators 25

Generics in Mexico 27

Market Overview 27

Market Data 28

Market Segmentation 30

Market outlook 31

Five forces analysis 33

Macroeconomic indicators 39

Generics in The United States 41

Market Overview 41

Market Data 42

Market Segmentation 44

Market outlook 45

Five forces analysis 47

Macroeconomic indicators 53

Company Profiles 55

Leading Companies 55

Appendix 72

Methodology 72

About MarketLine 73


List Of Figure

List of Figures

Figure 1: NAFTA countries generics industry, revenue (USD m), 2013-22

Figure 2: NAFTA countries generics industry, revenue (USD m), 2013-17

Figure 3: NAFTA countries generics industry forecast, revenue (USD m), 2017-22

Figure 4: Canada generics market value: USD million, 2013-17

Figure 5: Canada generics market volume: % of total pharma, 2013-17

Figure 6: Canada generics market geography segmentation: % share, by value, 2017

Figure 7: Canada generics market value forecast: USD million, 2017-22

Figure 8: Canada generics market volume forecast: % of total pharma, 2017-22

Figure 9: Forces driving competition in the generics market in Canada, 2017

Figure 10: Drivers of buyer power in the generics market in Canada, 2017

Figure 11: Drivers of supplier power in the generics market in Canada, 2017

Figure 12: Factors influencing the likelihood of new entrants in the generics market in Canada, 2017

Figure 13: Factors influencing the threat of substitutes in the generics market in Canada, 2017

Figure 14: Drivers of degree of rivalry in the generics market in Canada, 2017

Figure 15: Mexico generics market value: USD million, 2013-17

Figure 16: Mexico generics market volume: % of total pharma, 2013-17

Figure 17: Mexico generics market geography segmentation: % share, by value, 2017

Figure 18: Mexico generics market value forecast: USD million, 2017-22

Figure 19: Mexico generics market volume forecast: % of total pharma, 2017-22

Figure 20: Forces driving competition in the generics market in Mexico, 2017

Figure 21: Drivers of buyer power in the generics market in Mexico, 2017

Figure 22: Drivers of supplier power in the generics market in Mexico, 2017

Figure 23: Factors influencing the likelihood of new entrants in the generics market in Mexico, 2017

Figure 24: Factors influencing the threat of substitutes in the generics market in Mexico, 2017

Figure 25: Drivers of degree of rivalry in the generics market in Mexico, 2017

Figure 26: United States generics market value: USD billion, 2013-17

Figure 27: United States generics market volume: % of total pharma, 2013-17

Figure 28: United States generics market geography segmentation: % share, by value, 2017

Figure 29: United States generics market value forecast: USD billion, 2017-22

Figure 30: United States generics market volume forecast: % of total pharma, 2017-22

Figure 31: Forces driving competition in the generics market in the United States, 2017

Figure 32: Drivers of buyer power in the generics market in the United States, 2017

Figure 33: Drivers of supplier power in the generics market in the United States, 2017

Figure 34: Factors influencing the likelihood of new entrants in the generics market in the United States, 2017

Figure 35: Factors influencing the threat of substitutes in the generics market in the United States, 2017

Figure 36: Drivers of degree of rivalry in the generics market in the United States, 2017

Figure 37: Mylan N.V.: revenues & profitability

Figure 38: Mylan N.V.: assets & liabilities

Figure 39: Novartis AG: revenues & profitability

Figure 40: Novartis AG: assets & liabilities

Figure 41: Pfizer Inc.: revenues & profitability

Figure 42: Pfizer Inc.: assets & liabilities

Figure 43: Teva Pharmaceutical Industries Limited: revenues & profitability

Figure 44: Teva Pharmaceutical Industries Limited: assets & liabilities


List Of Table

List of Tables

Table 1: NAFTA countries generics industry, revenue (USD m), 2013-22

Table 2: NAFTA countries generics industry, revenue (USD m), 2013-17

Table 3: NAFTA countries generics industry forecast, revenue (USD m), 2017-22

Table 4: Canada generics market value: USD million, 2013-17

Table 5: Canada generics market volume: % of total pharma, 2013-17

Table 6: Canada generics market geography segmentation: USD million, 2017

Table 7: Canada generics market value forecast: USD million, 2017-22

Table 8: Canada generics market volume forecast: % of total pharma, 2017-22

Table 9: Canada size of population (million), 2013-17

Table 10: Canada gdp (constant 2005 prices, USD billion), 2013-17

Table 11: Canada gdp (current prices, USD billion), 2013-17

Table 12: Canada inflation, 2013-17

Table 13: Canada consumer price index (absolute), 2013-17

Table 14: Canada exchange rate, 2013-17

Table 15: Mexico generics market value: USD million, 2013-17

Table 16: Mexico generics market volume: % of total pharma, 2013-17

Table 17: Mexico generics market geography segmentation: USD million, 2017

Table 18: Mexico generics market value forecast: USD million, 2017-22

Table 19: Mexico generics market volume forecast: % of total pharma, 2017-22

Table 20: Mexico size of population (million), 2013-17

Table 21: Mexico gdp (constant 2005 prices, USD billion), 2013-17

Table 22: Mexico gdp (current prices, USD billion), 2013-17

Table 23: Mexico inflation, 2013-17

Table 24: Mexico consumer price index (absolute), 2013-17

Table 25: Mexico exchange rate, 2013-17

Table 26: United States generics market value: USD billion, 2013-17

Table 27: United States generics market volume: % of total pharma, 2013-17

Table 28: United States generics market geography segmentation: USD billion, 2017

Table 29: United States generics market value forecast: USD billion, 2017-22

Table 30: United States generics market volume forecast: % of total pharma, 2017-22

Table 31: United States size of population (million), 2013-17

Table 32: United States gdp (constant 2005 prices, USD billion), 2013-17

Table 33: United States gdp (current prices, USD billion), 2013-17

Table 34: United States inflation, 2013-17

Table 35: United States consumer price index (absolute), 2013-17

Table 36: United States exchange rate, 2013-17

Table 37: Apotex, Inc.: key facts

Table 38: Mylan N.V.: key facts

Table 39: Mylan N.V.: key financials (USD )

Table 40: Mylan N.V.: key financial ratios

Table 41: Novartis AG: key facts

Table 42: Novartis AG: key financials (USD )

Table 43: Novartis AG: key financial ratios

Table 44: Pfizer Inc.: key facts

Table 45: Pfizer Inc.: key financials (USD )

Table 46: Pfizer Inc.: key financial ratios

Table 47: Teva Pharmaceutical Industries Limited: key facts

Table 48: Teva Pharmaceutical Industries Limited: key financials (USD )

Table 49: Teva Pharmaceutical Industries Limited: key financial ratios

Single User License:
Report can be used by individual purchaser only

Site License: 
Report can be shared by unlimited users within one corporate location, e.g. a regional office

Corporate User License:  
Report can be shared globally by unlimited users within the purchasing corporation e.g. all employees of a single company

To know more information on Purchase by Section, please send a mail to support@kenresearch.com

Products

MarketLine, Pharmaceuticals and Healthcare, Generics , NAFTA